CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 26, 2007--POZEN Inc.
(NASDAQ: POZN) announced today that William L. Hodges, the company's
chief financial officer, will present at the BMO Capital Markets 2007
Focus on Healthcare Conference on Tuesday, December 4, 2007 at 10:00
a.m. (ET) at the Millennium Broadway Hotel in New York City. Mr.
Hodges' presentation will be webcast and archived on POZEN's home page
POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. POZEN's
efforts are focused primarily on the development of pharmaceutical
products for the treatment of acute and chronic pain and other
pain-related conditions. POZEN has development and commercialization
alliances with GlaxoSmithKline for the proposed product candidate
Trexima(TM) combining sumatriptan, formulated with RT Technology(TM),
and naproxen sodium in a single tablet for the acute treatment of
migraine, which is currently under review by the United States Food
and Drug Administration, and with AstraZeneca for the proprietary
fixed dose combination of the proton pump inhibitor esomeprazole
magnesium with naproxen in a single tablet for conditions such as
osteoarthritis and rheumatoid arthritis in patients who are at risk
for developing NSAID-associated gastric ulcers. The company's common
stock is traded on The Nasdaq Stock Market under the symbol "POZN".
For detailed company information, including copies of this and other
press releases, see POZEN's website: www.pozen.com.
CONTACT: POZEN Inc.
Bill Hodges, Chief Financial Officer, 919-913-1030
Fran Barsky, Director, Investor Relations, 919-913-1044
SOURCE: POZEN Inc.